 BiondVax Pharmaceuticals Ltd. BVXV secured a grant from the Israel Investment Center, a unit of the Government of Israels Ministry of Economy and Industry, to build a manufacturing facility for the production of Phase 3 and commercial batches of its universal flu vaccine, M-001. Influenza viruses often undergo changes to certain surface proteins which results in development of new virus strains that are unfamiliar to the human body immune system. The bigger the surface protein change, the lower the possibility of bodys immune system to fight against the disease. 